PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34933185-5 2021 We, therefore, examined whether a dual orexin receptor antagonist, suvorexant, administered following evening exposure sessions, would enhance their therapeutic effectiveness for PTSD. suvorexant 67-77 hypocretin neuropeptide precursor Homo sapiens 39-45 34497544-3 2021 The present study examined the utility of magnetic resonance spectroscopy (MRS) for detecting neural and/or glial changes in the VTA to distinguish responders from non-responders before treatment with the orexin receptor antagonist suvorexant. suvorexant 232-242 hypocretin neuropeptide precursor Homo sapiens 205-211 30619717-2 2019 We investigated suvorexant (an anti-insomnia drug that targets the orexin system) effects on sleep architecture and glucose metabolism in T2DM patients with insomnia. suvorexant 16-26 hypocretin neuropeptide precursor Homo sapiens 67-73 35022783-2 2022 We tested the efficacy of the dual orexin receptor antagonist suvorexant for chronic insomnia related to nighttime VMS. suvorexant 62-72 hypocretin neuropeptide precursor Homo sapiens 35-41 32669442-3 2020 The nonselective orexin receptor antagonist suvorexant has been the first drug on the market targeting the orexin system and is prescribed for the treatment of insomnia. suvorexant 44-54 hypocretin neuropeptide precursor Homo sapiens 17-23 32224066-3 2020 Our recent research revealed that suvorexant, a dual orexin receptor antagonist, could improve behavioral circadian rhythm disorders in 9-month-old APP/PS1 mice. suvorexant 34-44 hypocretin neuropeptide precursor Homo sapiens 53-59 28584695-0 2017 Neuroendocrine, Autonomic, and Metabolic Responses to an Orexin Antagonist, Suvorexant, in Psychiatric Patients with Insomnia. suvorexant 76-86 hypocretin neuropeptide precursor Homo sapiens 57-63 29289556-8 2018 Hyper-activation of the orexin system also causes sleep disturbances, such as insomnia, and hence, suvorexant, an orexin receptor antagonist, has been clinically used to treat insomnia. suvorexant 99-109 hypocretin neuropeptide precursor Homo sapiens 24-30 29289556-8 2018 Hyper-activation of the orexin system also causes sleep disturbances, such as insomnia, and hence, suvorexant, an orexin receptor antagonist, has been clinically used to treat insomnia. suvorexant 99-109 hypocretin neuropeptide precursor Homo sapiens 114-120 28994603-4 2017 By blocking orexin receptors, suvorexant induces sleep. suvorexant 30-40 hypocretin neuropeptide precursor Homo sapiens 12-18 28945327-0 2017 Suvorexant as an orexin antagonist may regulate serum glucose levels in psychiatric patients with insomnia. suvorexant 0-10 hypocretin neuropeptide precursor Homo sapiens 17-23 27390287-1 2016 Starting from suvorexant (trade name Belsomra), we successfully identified interesting templates leading to potent dual orexin receptor antagonists (DORAs) via a scaffold-hopping approach. suvorexant 14-24 hypocretin neuropeptide precursor Homo sapiens 120-126 27860547-0 2017 The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia. suvorexant 17-27 hypocretin neuropeptide precursor Homo sapiens 39-45 27909991-6 2017 The orexin (hypocretin) neuropeptide system is an attractive target, given the recent FDA and PMDA approval of suvorexant for the treatment of insomnia. suvorexant 111-121 hypocretin neuropeptide precursor Homo sapiens 4-10 23359095-6 2013 Indeed, phase III clinical trials were completed last year of suvorexant, a non-selective (dual) antagonist for orexin receptors, for the treatment of primary insomnia, and demonstrate promising results. suvorexant 62-72 hypocretin neuropeptide precursor Homo sapiens 112-118 26864332-2 2016 Suvorexant (MK-4305, Belsomra ) is a first-in-class dual orexin receptor antagonist approved in the USA and Japan for the treatment of insomnia. suvorexant 0-10 hypocretin neuropeptide precursor Homo sapiens 57-63 26864332-2 2016 Suvorexant (MK-4305, Belsomra ) is a first-in-class dual orexin receptor antagonist approved in the USA and Japan for the treatment of insomnia. suvorexant 12-19 hypocretin neuropeptide precursor Homo sapiens 57-63 25227290-1 2014 Suvorexant (Belsomra( )), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia. suvorexant 0-10 hypocretin neuropeptide precursor Homo sapiens 63-69 25227290-1 2014 Suvorexant (Belsomra( )), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia. suvorexant 0-10 hypocretin neuropeptide precursor Homo sapiens 85-91 25197807-1 2014 STUDY OBJECTIVES: Suvorexant, an orexin receptor antagonist, improves sleep in healthy subjects (HS) and patients with insomnia. suvorexant 18-28 hypocretin neuropeptide precursor Homo sapiens 33-39 24680372-1 2014 BACKGROUND: Suvorexant (MK-4305) is an orexin receptor antagonist shown to be efficacious for insomnia over 3 months. suvorexant 12-22 hypocretin neuropeptide precursor Homo sapiens 39-45 24680372-1 2014 BACKGROUND: Suvorexant (MK-4305) is an orexin receptor antagonist shown to be efficacious for insomnia over 3 months. suvorexant 24-31 hypocretin neuropeptide precursor Homo sapiens 39-45 27253658-0 2016 Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. suvorexant 69-79 hypocretin neuropeptide precursor Homo sapiens 41-47 27253658-1 2016 Suvorexant is a dual orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia at a maximum dose of 20 mg. suvorexant 0-10 hypocretin neuropeptide precursor Homo sapiens 21-27 26317591-5 2016 The work described herein culminated in the 2014 FDA approval of suvorexant as a first-in-class dual orexin receptor antagonist for the treatment of insomnia. suvorexant 65-75 hypocretin neuropeptide precursor Homo sapiens 101-107 25969666-0 2015 Suvorexant: The first orexin receptor antagonist to treat insomnia. suvorexant 0-10 hypocretin neuropeptide precursor Homo sapiens 22-28 25969666-2 2015 A novel approach to treat insomnia has been introduced recently, with the approval of suvorexant, the first in a new class of orexin receptor antagonists. suvorexant 86-96 hypocretin neuropeptide precursor Homo sapiens 126-132 25397996-3 2015 Suvorexant helps in decreasing wakefulness by counteracting orexin activity. suvorexant 0-10 hypocretin neuropeptide precursor Homo sapiens 60-66 24592206-3 2014 The filing to FDA of the dual-activity orexin receptor antagonist (DORA) suvorexant for the indication of insomnia further corroborates the robustness of such evidences. suvorexant 73-83 hypocretin neuropeptide precursor Homo sapiens 39-45 22725839-1 2012 A concise, enantioselective synthesis of the potent dual orexin inhibitor suvorexant (1) is reported. suvorexant 74-84 hypocretin neuropeptide precursor Homo sapiens 57-63 22920041-4 2012 Merck"s suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor antagonist (DORA) class expected to be submitted for FDA approval, with a new drug application anticipated in 2012. suvorexant 8-18 hypocretin neuropeptide precursor Homo sapiens 73-79 22920041-4 2012 Merck"s suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor antagonist (DORA) class expected to be submitted for FDA approval, with a new drug application anticipated in 2012. suvorexant 20-27 hypocretin neuropeptide precursor Homo sapiens 73-79 23024835-1 2012 Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. suvorexant 0-10 hypocretin neuropeptide precursor Homo sapiens 21-27 21528938-0 2011 Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual Orexin inhibitor Suvorexant (MK-4305). suvorexant 152-162 hypocretin neuropeptide precursor Homo sapiens 135-141 21528938-0 2011 Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual Orexin inhibitor Suvorexant (MK-4305). suvorexant 164-171 hypocretin neuropeptide precursor Homo sapiens 135-141 21528938-1 2011 The first example of an intramolecular asymmetric reductive amination of a dialkyl ketone with an aliphatic amine has been developed for the synthesis of Suvorexant (MK-4305), a potent dual Orexin antagonist under development for the treatment of sleep disorders. suvorexant 154-164 hypocretin neuropeptide precursor Homo sapiens 190-196 21528938-1 2011 The first example of an intramolecular asymmetric reductive amination of a dialkyl ketone with an aliphatic amine has been developed for the synthesis of Suvorexant (MK-4305), a potent dual Orexin antagonist under development for the treatment of sleep disorders. suvorexant 166-173 hypocretin neuropeptide precursor Homo sapiens 190-196